Similar to CD133, CD166+ prostate cancer cells have stronger ability of regeneration and proliferation and can produce primitive tumor heterogeneity in xenografts, while knockout of CD166 could inhibit tumor growth 29. Here, PROM1 is linked to neoplasm.